Co-Authors
This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and STEVEN I SHERMAN.
Connection Strength
0.534
-
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer. 2010 Jun 15; 116(12):2974-83.
Score: 0.096
-
Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck. 2009 Sep; 31(9):1152-63.
Score: 0.091
-
Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol. 2009 Jun; 40(6):827-33.
Score: 0.087
-
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008 Jan; 93(1):278-84.
Score: 0.080
-
Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008 Jan; 39(1):15-20.
Score: 0.080
-
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005.
Score: 0.025
-
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8.
Score: 0.023
-
Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid. 2008 Aug; 18(8):901-5.
Score: 0.021
-
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8594-602.
Score: 0.016
-
Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
Score: 0.016